Phenolsulfonic Acid

Phenolsulfonic Acid

SCHEMBL119166

O=S(=O)(O)c1ccc(O)cc1.[CaH2]

nearest known ligand 0.94

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.94
ALDH1A1 P00352 5/20 0.56
CA2 P00918 4/20 0.56
CA12 O43570 3/20 0.56
CA9 Q16790 3/20 0.56
TSHR P16473 2/20 0.56
CA1 P00915 2/20 0.56
NT5E P21589 1/20 0.56
ENPP2 Q13822 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.55
TDP1 Q9NUW8 1/20 0.50
HSD17B10 Q99714 4/20 0.46
POLB P06746 1/20 0.46
CYP2D6 P10635 1/20 0.46
GAA P10253 1/20 0.45
PKM P14618 1/20 0.45
CA7 P43166 1/20 0.45
HPGD P15428 3/20 0.44
KDM4E B2RXH2 3/20 0.44
CYP3A4 P08684 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phenolsulfonic Acid SCHEMBL10622999 0.97 LMNA (1.00) LMNAALDH1A1CA2CA12CA9
Phenolsulfonic Acid SCHEMBL29965481 0.97 LMNA (1.00) LMNAALDH1A1CA2CA12CA9
Phenolsulfonic Acid SCHEMBL18275 0.97 LMNA (1.00) LMNAALDH1A1CA2CA12CA9
Phenolsulfonic Acid SCHEMBL687364 0.94 LMNA (0.94) LMNAALDH1A1CA2CA12CA9
Phenolsulfonic Acid SCHEMBL20815893 0.94 LMNA (0.94) LMNAALDH1A1CA2CA12CA9
Phenolsulfonic Acid SCHEMBL2518117 0.94 LMNA (0.94) LMNAALDH1A1CA2CA12CA9
Phenolsulfonic Acid SCHEMBL9682015 0.94 LMNA (0.94) LMNAALDH1A1CA2CA12CA9
Phenolsulfonic Acid SCHEMBL560246 0.94 LMNA (0.94) LMNAALDH1A1CA2CA12CA9
Phenolsulfonic Acid SCHEMBL8781964 0.94 LMNA (0.94) LMNAALDH1A1CA2CA12CA9
Phenolsulfonic Acid SCHEMBL125057 0.94 LMNA (0.94) LMNAALDH1A1CA2CA12CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11850294-B2 Buffered microencapsulated compositions and methods PREMIER DENTAL PRODUCTS COMPANY (US) 2023-12-26 US claimed
CN-116574037-A Continuous synthesis method of calcium dobesilate 宁夏元康药业有限公司 2023-08-11 CN claimed
US-20220079849-A1 BUFFERED MICROENCAPSULATED COMPOSITIONS AND METHODS FIDELITY DIRECT LENDING LLC, AS ADMINISTRATIVE AGENT 2022-03-17 US claimed
EP-1868940-B1 OBTAINING AMMONIUM DINITRAMIDE (ADN) CRYSTALS HERAKLES (FR) 2017-09-20 EP claimed
US-7789980-B2 Preparation of ammonium dinitroamide (ADN) crystals, ADN crystals and energetic composites containing them SNPE MATERIAUX ENERGETIQUES (FR) 2010-09-07 US claimed
US-20090090441-A1 Preparation of Ammonium Dinitroamide (ADN) Crystals, ADN Crystals and Energetic Composites Containing Them SNPE MATERIAUX ENERGETIQUES (FR) 2009-04-09 US claimed
CN-114839293-B Quantitative determination method for genotoxic impurities in calcium dobesilate 南京长澳医药科技有限公司 2024-05-17 CN disclosed
CN-114839293-B Quantitative determination method for genotoxic impurities in calcium dobesilate 南京长澳医药科技有限公司 2024-05-17 CN disclosed
CN-114380723-A Para hydroxybenzene sulfonate compound and preparation method and application thereof 成都益安成贸易有限公司 2022-04-22 CN disclosed
CN-113744821-A Information detection method and device and storage medium 北京京东拓先科技有限公司 2021-12-03 CN disclosed
CN-109280306-A A kind of preparation method of Polymethacrylimide composite foam conduction absorbing material 浙江中科恒泰新材料科技有限公司 2019-01-29 CN disclosed
CN-103597021-B Irradiated fluoropolymer articles with low leachable fluoride ions ARKEMA INC. (US) 2015-11-25 CN disclosed
US-8889161-B2 Microencapsulated compositions and methods for tissue mineralization PREMIER DENTAL PRODUCTS COMPANY (US) 2014-11-18 US disclosed
CN-1757389-A Implanted agent for preventing and treating biabetic retinopathy DUAN YADONG (CN) 2006-04-12 CN disclosed
CN-1037007-C Oil-soluble adducts of disuccinimides and anhydrides of unsaturated bicarboxylic aliphatic acids AGIP PETROLI (IT) 1998-01-14 CN disclosed
CN-1101934-A Oil-soluble adducts of disuccinimides and anhydrides of unsaturated bicarboxylic aliphatic acids AGIP PETROLI (IT) 1995-04-26 CN disclosed
EP-0125641-B1 ALKANOYLOXYBENZENESULFONATE SALT PRODUCTION ETHYL CORPORATION (US) 1987-03-04 EP disclosed
US-4544503-A REACTING HYDROXY BENZENESULFONATE WITH CARBON MONOXIDE AND OLEFIN ETHYL CORPORATION (US) 1985-10-01 US disclosed
US-4537724-A Alkanoyloxybenzenesulfonate salt production ETHYL CORPORATION (US) 1985-08-27 US disclosed
EP-0125641-A2 Alkanoyloxybenzenesulfonate salt production ETHYL CORPORATION (US) 1984-11-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11850294-B2 Buffered microencapsulated compositions and methods CHMP4B, LIPA, APOB LMNA 930/4885ALDH1A1 3804/4885CA2 690/4885
US-20220079849-A1 BUFFERED MICROENCAPSULATED COMPOSITIONS AND METHODS CHMP4B, LIPA, APOB LMNA 930/4885ALDH1A1 3804/4885CA2 690/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.